Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

Biotech stocks have long enticed investors with the promise of outsized gains. Amid recent federal policy shifts, two ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

By Priya Kalia, SciTribe and Miranda Weston-Smith, BioBeat.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Don’t see coverage of an asset you’re looking for? Let us know and we’ll add it to future snacks.